Our preliminary data with an in vivo experimental model of CRC hepatic metastases implied that the GREM1-neutralizing antibody still requires further optimization of the therapeutic setting (metastatic prevention vs treatment), dosage regimens, route of administration, and in combination with other agents. This evidence concerns the gene GREM1 and colorectal carcinoma.